Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tideglusib in Mild-to-Moderate Alzheimer's Disease (ARGO)
NCT01350362Phase 2Completed
- Sponsor
- Noscira S.A.
- Start
- Apr 2011
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of tideglusib in Alzheimer's disease (AD) (4 arms), sponsored by Noscira S.A. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 26 weeks. Started Apr 2011; status: completed.
02
Drugs
tideglusib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01350362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01350362.